Next Generation Tumor Targets
Targeting novel tumor antigens for greater specificity and multifunctional anti-tumor activity.
A New Chapter
Synergy Immunotherapeutics (IMT), is dedicated to developing highly effective cancer treatments for patients in need.
Anti-solid tumor drugs frequently fail due to multiple protumor activities of the tumor microenvironment (TME). Increased dosing in an attempt to overcome the physical and immunosuppressive barriers of the TME often results in severe toxicities. A novel cancer target discovery platform enables generation of immunotherapeutics that can disrupt the TME barrier and allow more effective tumor killing without severe dose-limiting toxicities. It therefore addresses the most pressing clinical barriers for solid tumor treatment.
A novel cancer target discovery platform enables generation of immunotherapeutics that can disrupt the TME barrier and allow more effective tumor killing without severe dose-limiting toxicities. It therefore addresses the most pressing clinical barriers for solid tumor treatment.
Novel tumor antigens are identified that are intracellular in normal cells but locate to the surface of tumor cells and highly stressed critical pro-tumor cells within the TME. Their intracellular expression in normal cells enables maximal effective drug dosing without severe toxicities due to on-target off-tumor/TME cytotoxic activity.
Potent tumor cytotoxicity is demonstrated with immunotherapeutics specific for these stress/survival tumor antigens (sTA) and a pilot safety study indicates that they are well tolerated.
Emerging Therapeutic Solutions
Novel tumor antigens have been effectively targeted with monospecific antibodies, antibody drug conjugates (ADCs), T cell engagers (TCE) and with innovative multispecific recombinant antibodies and proteins. Given the properties of the tumor antigens, there is high potential for a novel adjuvant or stand-alone therapeutic and for synergy with certain approved cancer therapeutics to kill tumor cells and induce or revitalize an anti-tumor immune response. AI is integrated to accelerate and enhance development from discovery to investigative new drug.
